Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request